Prediction of survival in patients with Stage IV kidney cancer
https://doi.org/10.17650/1726-9776-2015-1-30-40
Abstract
The efficiency of treatment was evaluated and the predictors of adjusted survival (AS) were identified in patients with disseminated kidney cancer treated at the Republican Research and Practical Center for Oncology and Medical Radiology in 1999 to 2011 (A.E. Okeanov, P.I. Moiseev, L.F. Levin. Malignant tumors in Belarus, 2001–2012. Edited by O.G. Sukonko). Seven factors (regional lymph node metastases; distant bone metastases; a high-grade tumor; sarcomatous tumor differentiation; hemoglobin levels of < 125 g/l in women and < 150 g/l in men; an erythrocyte sedimentation rate of 40 mm/h; palliative surgery) were found to have an independent, unfavorable impact on AS. A multidimensional model was built to define what risk group low (no more than 2 poor factors), moderate (3–4 poor factors), and high (more than 4 poor factors)) the patients with Stage IV kidney cancer belonged to. In these groups, the median survival was 34.7, 17.2, and 4.0 months and 3-year AS rates were 48.6, 24.6, and 3.2 %, respectively.
About the Authors
L. V. Mirilenko
N.N. Aleksandrov Republican Research and Practical Center for Oncology and Medical Radiology; Lesnoy Agrotown, Minsk District, Minsk Region 223 040, Republic of Belarus
Russian Federation
Russian Federation
A. B. Poluyanchik
N.N. Aleksandrov Republican Research and Practical Center for Oncology and Medical Radiology; Lesnoy Agrotown, Minsk District, Minsk Region 223 040, Republic of Belarus
Russian Federation
Russian Federation
References
1. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics: 1999. CA Cancer J Clin 1999;49:8–31.
2. Pantuck A.J., Zisman A., Belldegrun A.S. The changing natural history of renal cell carcinoma. J Urol 2001;166:1611–23.
3. Океанов А.Е., Моисеев П.И., Левин Л.Ф. Злокачественные новообразования в Беларуси, 2001–2012. Под ред. О.Г. Суконко. Минск: РНПЦ ОМР, 2013. 373 с. [Okeanov A.E., Moiseev P.I.,
4. Levin L.F.. Malignant tumors in Belarus, 2001–2012. Edit. by O.G. Sukonko (In Russ.)].
5. Motzer R.J., Mazumdar M., Bacik J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530–40.
6. Heng D.Y., Xie W., Regan M.M. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factortargeted agents: results from a large, multicenter study. J Clin Oncol 2009;27(34):5794–9.
7. Mazumdar M., Glassman J. Categorizing a prognostic variable: Review of methods, codes for easy implementation and application to decision-making about cancer treatments. Stat Med 2000;19(1):113–32.
8. Tietz clinical guide to laboratory tests–4th ed. Edited by Alan H.B.Wu. 2006
9. Harrell F.E. Jr. Regression modeling strategies with applications to linear models, logistic regression, and survival analysis. NY: Springer Verlag, 2001. P. 279–281.
Review
For citations:
Mirilenko L.V., Poluyanchik A.B. Prediction of survival in patients with Stage IV kidney cancer. Cancer Urology. 2015;11(1):30-40. (In Russ.) https://doi.org/10.17650/1726-9776-2015-1-30-40
Views:
1393
Email this article 